A phase 2 study of quizartinib in Japanese patients with R/R FLT3-ITD + AML reported a similar rate of CRc (54%) to that observed with gilteritinib (58%) in the Japanese subgroup from the ADMIRAL trial [36]. This evidence concerns the gene FLT3 and acute myeloid leukemia.